If a patient were to suffer an adverse outcome potentially linked to BPC-157, the physician could be found liable for using an unauthorized treatment
All communication with your prescribing physician, the MWLCOA admin team, and the pharmacy will take place securely through your HIPAA-compliant patient portal
Available information derives from animal studies or from mechanistic reasoning
PMC Early clinical safety work: Phase 1/2 investigations with T4 examined IV/topical use and general tolerability, but did not establish approved indications
Using receptor antagonists against NK1 and NK3 receptors in porcine tracheal explants, Philips and colleagues showed that SubP and NKB induced submucosal gland fluid flux, while NKA had no effect on the gland flux [80]
This helps them tailor the treatment to your specific needs and identify any potential risks